CIK 0001840439 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Biomea Fusion, Inc.
Sign in to watch- Ticker
- BMEA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (650) 980-9099
- Business address
- 1599 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-29 | Erdtmann Rainer M President and COO | Gift | +3,000 | 9,400 | ||
| 2023-12-29 | Erdtmann Rainer M President and COO | Gift | −3,000 | 728,027 | ||
| 2023-12-29 | Erdtmann Rainer M President and COO | Gift | +3,000 | 10,000 | ||
| 2023-12-29 | Erdtmann Rainer M President and COO | Gift | −3,000 | 725,027 | ||
| 2023-12-29 | Erdtmann Rainer M President and COO | Gift | +3,000 | 10,000 | ||
| 2023-12-29 | Erdtmann Rainer M President and COO | Gift | −12,000 | 713,027 | ||
| 2023-11-30 | Valle Franco Chief Financial Officer | Grant or award | +1,345 | $3.78 | $5K | 25,543 |
| 2023-08-31 | Frias Juan Pablo Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2023-06-14 | Hitchcock Michael J.M. Director | Grant or award · Stock Option (Right to Buy) | +6,989 | 6,989 | ||
| 2023-06-14 | Faust Elizabeth Director | Grant or award · Stock Option (Right to Buy) | +6,989 | 6,989 | ||
| 2023-06-14 | Ray Sumita Director | Grant or award · Stock Option (Right to Buy) | +6,989 | 6,989 | ||
| 2023-06-14 | AGUIAR ERIC Director | Grant or award · Stock Option (Right to Buy) | +6,989 | 6,989 | ||
| 2023-06-14 | Chen Bihua Director | Grant or award · Stock Option (right to buy) | +6,989 | 6,989 | ||
| 2023-06-01 | A2A Pharmaceuticals, Inc. 10% owner | Sale | −50,000 | $34.56 | $1.7M | 3,500,000 |
| 2023-05-31 | A2A Pharmaceuticals, Inc. 10% owner | Sale | −75,000 | $33.81 | $2.5M | 3,550,000 |
| 2023-05-31 | Valle Franco Chief Financial Officer | Grant or award | +4,273 | $3.78 | $16K | 24,198 |
| 2023-05-12 | A2A Pharmaceuticals, Inc. 10% owner | Sale | −25,000 | $33.84 | $846K | 3,625,000 |
| 2023-05-09 | A2A Pharmaceuticals, Inc. 10% owner | Sale | −150,000 | $34.50 | $5.2M | 3,650,000 |
| 2023-05-08 | A2A Pharmaceuticals, Inc. 10% owner | Sale | −100,000 | $33.99 | $3.4M | 3,800,000 |
| 2023-04-20 | A2A Pharmaceuticals, Inc. 10% owner | Sale | −200,000 | $29.12 | $5.8M | 3,900,000 |
Page 3 of 6 · 106 trades